Article Information
History
- October 18, 2020.
Article Versions
- Version 1 (October 14, 2020 - 06:13).
- You are currently viewing Version 2 of this article (October 18, 2020 - 15:12).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Ariel Israel, M.D., Ph.D.1,*,
- Alejandro A. Schäffer, Ph.D.3,
- Assi Cicurel, M.D., M.B.A.1,2,
- Ilan Feldhamer, M.A.1,
- Ameer Tal, M.Sc.1,
- Kuoyuan Cheng, M.S.3,
- Sanju Sinha, B.Tech.3,
- Eyal Schiff, MD4,
- Gil Lavie, M.D., M.H.A., M.B.A.1,5,# and
- Eytan Ruppin, M.D., Ph.D.3,#
- 1Division of Planning and Strategy, Clalit Health Services, Israel
- 2Clalit Health Services, Southern District and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
- 3Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
- 4Sheba Medical Center, Tel-Aviv University, Israel
- 5Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel
- ↵*Corresponding Author: Ariel Israel, MD, PhD, Director, Department of Research and Data, Division of Planning and Strategy, Clalit Health Services, 101 Arlozorov Street, Tel Aviv 62098, Israel, Telephone: +972-3-3948160, Email: dr.ariel.israel{at}gmail.com
↵# Equal contribution last authors
Posted October 18, 2020.
Large population study identifies drugs associated with reduced COVID-19 severity
